{"organizations": [], "uuid": "60d61244380676712241bdf5ec7d83635b030d63", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/19/business-wire-andrew-berens-m-d-joins-leerink-partners-equity-research-team.html", "country": "US", "domain_rank": 767, "title": "Andrew Berens, M.D. Joins LEERINK Partners Equity Research Team", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-04-19T17:00:00.000+03:00", "replies_count": 0, "uuid": "60d61244380676712241bdf5ec7d83635b030d63"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/19/business-wire-andrew-berens-m-d-joins-leerink-partners-equity-research-team.html", "ord_in_thread": 0, "title": "Andrew Berens, M.D. Joins LEERINK Partners Equity Research Team", "locations": [], "entities": {"persons": [{"name": "andrew berens", "sentiment": "negative"}, {"name": "berens", "sentiment": "none"}], "locations": [{"name": "boston", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}, {"name": "tulane", "sentiment": "none"}], "organizations": [{"name": "leerink partners equity research team", "sentiment": "negative"}, {"name": "columbia business school", "sentiment": "none"}, {"name": "emory university", "sentiment": "none"}, {"name": "america research team for biotechnology/mid- & small-cap", "sentiment": "none"}, {"name": "equity research", "sentiment": "none"}, {"name": "ikaria pharmaceuticals", "sentiment": "none"}, {"name": "london business school", "sentiment": "none"}, {"name": "morgan stanley", "sentiment": "none"}, {"name": "senior biotechnology research analyst", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BOSTON--(BUSINESS WIRE)-- LEERINK Partners, a leading healthcare investment bank, announced today the hiring of Andrew Berens, M.D. to the firm’s Equity Research team. Dr. Berens will join the firm in June as a Managing Director, Senior Research Analyst within the Therapeutics team and will be located in their New York office.\nDr. Berens joins LEERINK Partners from Morgan Stanley where he was an Executive Director and Senior Biotechnology Research Analyst focusing on mid and small cap biotechnology companies. In 2017 he was named a Runner Up in Institutional Investor’s 2017 All–America Research Team for Biotechnology/Mid- & Small-Cap. Dr. Berens practiced as an emergency medicine physician for a decade before starting his career in equity research. He also worked in the pharma industry at Ikaria Pharmaceuticals, where he was a Senior Director in business development, leading search and development efforts.\nDr. Berens earned MBA degrees from Columbia Business School and London Business School, his M.D. from Emory University and an undergraduate degree in English Literature from Tulane University.\n“I’m pleased to welcome Andy to LEERINK Partners. Andy’s experience as a practicing physician and accomplished research professional, make him a strong addition to our firm. We are confident that Andy will further enhance our leading position in therapeutics research,” said John L. Sullivan, CFA, Director of Equity Research.\nGeoff Porges, Senior Biotechnology Analyst and Director of Therapeutics Research said, \"I am very excited for Andy to join our Therapeutics Research team. With his knowledge of the industry, markets, products, and companies he will be a great partner for our analysts and our clients.”\n“I am thrilled to be joining LEERINK Partners, which I consider to have the pre-eminent healthcare franchise on the Street. I look forward to working with Geoff and the highly specialized sales force to deliver in-depth, thoughtful, and actionable research to our clients,” stated Dr. Berens.\nAbout LEERINK Partners\nLEERINK Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. LEERINK Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com .\n //www.businesswire.com/news/home/20180419005298/en/\nLEERINK Partners\nDiane Vieira, 617-918-4097\nor\nWeber Shandwick\nKate Contreras, 617-520-7088\nSource: LEERINK Partners LLC", "external_links": ["https://www.businesswire.com/news/home/20180419005298/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.leerink.com&esheet=51791498&newsitemid=20180419005298&lan=en-US&anchor=www.leerink.com&index=1&md5=984043f92f3386aacac375a8e4a46c8e"], "published": "2018-04-19T17:00:00.000+03:00", "crawled": "2018-04-19T17:31:51.004+03:00", "highlightTitle": ""}